Substance / Medication

Asunaprevir

SNOMED 715390003 UMLS C3491974

Overview

Active Ingredient

asunaprevir

RxNorm CUI

1652103

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Cirrhosis of liver

Chronic type C viral hepatitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

102 trials linked to this intervention

102

Total Trials

Recruiting

With Results

Recent Trials

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

NCT00001854Phase 4Completed50 enrolled

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

NCT00028093Phase 4Completed50 enrolled

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636Phase 4Completed1469 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

NCT00077649Phase 4Completed188 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568Phase 4Completed57 enrolled

View all 102 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.

Ahmed Ali Mahmoud, Doheim Mohamed Fahmy, Mattar Omar Mohamed et al. · J Med Virol · 2018

PMID: 28892235Meta-Analysis

Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.

Wang Hui-Lian, Lu Xi, Yang Xudong et al. · J Gastroenterol Hepatol · 2017

PMID: 27597318Meta-Analysis

Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Toyoda Hidenori, Kumada Takashi, Tada Toshifumi et al. · J Gastroenterol · 2016

PMID: 26872889RCT

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

Pasquinelli Claudio, McPhee Fiona, Eley Timothy et al. · Antimicrob Agents Chemother · 2012

PMID: 22290978RCTFull text (PMC)

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study.

Yoon Jae-Hyun, Kim Sung-Eun, Cho Su-Hyeon et al. · Medicina (Kaunas) · 2023

PMID: 37629725ObservationalFull text (PMC)

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.

Oh Jae Young, Kim Byung Seok, Lee Chang Hyeong et al. · Korean J Intern Med · 2019

PMID: 29792020ObservationalFull text (PMC)

Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.

Takaguchi Koichi, Toyoda Hidenori, Tsutsui Akemi et al. · J Gastroenterol · 2019

PMID: 30848363Observational

Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.

Shin Seung Kak, Lee Jin Woo, Ra Hannah et al. · J Korean Med Sci · 2019

PMID: 31650719ObservationalFull text (PMC)

Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life.

Kawakubo Megumi, Eguchi Yuichiro, Okada Michiaki et al. · Intern Med · 2018

PMID: 29526929ObservationalFull text (PMC)

Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.

Kawakami Yoshiiku, Ochi Hidenori, Hayes Clair Nelson et al. · J Gastroenterol · 2018

PMID: 28815329Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Asunaprevir (substance)
SNOMED CT: 715390003
UMLS CUI: C3491974
RxNorm CUI: 1652103

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

102

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.